GILEAD SCIENCES, INC. - 10-Q Filing
Gilead Sciences filed a Form 10-Q for the first quarter of fiscal year 2026, reporting financial results and segment performance. The filing includes revenue details by product lines such as HIV treatments (e.g., Biktarvy), liver disease products (e.g., Vemlidy), oncology drugs like Trodelvy, and cell therapy products.
Tickers: $GILD